Table 1 Patient characteristics

From: Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women

Characteristic

Denosumab (n=13)

Combination (n=17)

P-value

Age/years

75.1±1.8

75.5±1.4

P=0.841 3

BMI/(kg·m−2)

20.9±0.9

21.4±1.0

P=0.717 1

Serum corrected Ca/(mg·dL−1)

9.0±0.1

9.0±0.1

P=0.917 5

Serum phosphorus/(mg·dL−1)

3.8±0.1

3.7±0.1

P=0.825 4

Serum BAP/(μg·L−1)

21.6±2.5

19.2±2.4

P=0.497 6

Serum TRACP-5b/(mU·dL−1)

587.5±33.5

571.5±48.8

P=0.788 6

Urinary NTX (nmol BCE per mmol CRE)

60.4±9.1

66.0±8.0

P=0.644 0

1, 25 (OH)2D3/(pg·mL−1)

56.1±5.6

58.2±4.3

P=0.773 4

Serum whole PTH/(pg·mL−1)

35.7±2.8

28.7±3.4

P=0.126 7

L1–4 BMD/(g·cm−2)

0.799±0.03

0.730±0.03

P=0.153 0

Total hip BMD/(g·cm−2)

0.64±0.03

0.62±0.01

P=0.456 3

  1. BAP, bone-specific alkaline phosphatase; BMD, bone mineral density; BMI, body mass index; NTX, N-terminal telopeptides of type I collagen; PTH, parathyroid hormone; TRACP, tartrate-resistant acid phosphatase.
  2. Results are expressed as mean±s.e.
  3. Differences of P<0.05 were considered significant.
Back to article page